• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry.

作者信息

Mato Anthony R, Ghosh Nilanjan, Sharman Jeff P, Brander Danielle, Gutierrez Meghan, Huang Qing, Wu Linda H, Young Alex, Upasani Sandhya, Naganuma Maoko, Barrientos Jacqueline C

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY.

Levine Cancer Institute, Atrium Health, Charlotte, NC.

出版信息

Blood Adv. 2023 Sep 12;7(17):4760-4764. doi: 10.1182/bloodadvances.2022008068.

DOI:10.1182/bloodadvances.2022008068
PMID:36206191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10468359/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abcd/10468359/2d0cacaee9f4/BLOODA_ADV-2022-008068-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abcd/10468359/2d0cacaee9f4/BLOODA_ADV-2022-008068-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abcd/10468359/2d0cacaee9f4/BLOODA_ADV-2022-008068-gr1.jpg

相似文献

1
Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的真实世界预后检测与治疗模式：来自informCLL注册研究中1462例患者的结果
Blood Adv. 2023 Sep 12;7(17):4760-4764. doi: 10.1182/bloodadvances.2022008068.
2
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.新型靶向治疗时代慢性淋巴细胞白血病的预后检测与治疗模式：来自informCLL注册研究的结果
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):174-183.e3. doi: 10.1016/j.clml.2019.10.009. Epub 2019 Oct 21.
3
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.根据荧光原位杂交/细胞遗传学分层的慢性淋巴细胞白血病患者的预后检测模式及结果：来自Connect CLL注册研究的真实临床经验
Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):114-124.e2. doi: 10.1016/j.clml.2017.11.010. Epub 2017 Dec 6.
4
Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).B 细胞慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（B-CLL/SLL）和套细胞淋巴瘤（MCL）的诊断与预后
J Egypt Natl Canc Inst. 2005 Dec;17(4):279-90.
5
CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.CD49d 在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的流式细胞术预后检测中具有优越的性能特征。
Cytometry B Clin Cytom. 2018 Jan;94(1):129-135. doi: 10.1002/cyto.b.21384. Epub 2016 Jun 27.
6
Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015.2006-2015 年台湾地区慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的流行病学、治疗模式和生存情况。
Int J Clin Pract. 2021 Aug;75(8):e14258. doi: 10.1111/ijcp.14258. Epub 2021 May 29.
7
Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia/small lymphocytic lymphoma.骨髓中单克隆 B 细胞淋巴增生：重新审视慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的标准。
Hum Pathol. 2022 Jul;125:108-116. doi: 10.1016/j.humpath.2022.04.010. Epub 2022 Apr 25.
8
MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).MUM1/IRF4表达是B细胞慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）中的一个不良预后因素。
Jpn J Cancer Res. 2002 Jun;93(6):685-94. doi: 10.1111/j.1349-7006.2002.tb01307.x.
9
Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.里希特转化型慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的结局：SEER 数据库分析。
Ann Hematol. 2021 Oct;100(10):2513-2519. doi: 10.1007/s00277-021-04603-y. Epub 2021 Jul 19.
10
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：同一疾病的两种表现。
Expert Rev Hematol. 2017 Feb;10(2):137-146. doi: 10.1080/17474086.2017.1270203. Epub 2016 Dec 26.

引用本文的文献

1
Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中一线治疗模式随虚弱状态的变化。
Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
2
Cause-Specific Mortality and Prognostic Impact of Comorbidity in Japanese Patients With Chronic Lymphocytic Leukemia.日本慢性淋巴细胞白血病患者的病因特异性死亡率及合并症的预后影响
Cancer Med. 2025 Feb;14(3):e70613. doi: 10.1002/cam4.70613.
3
Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis.

本文引用的文献

1
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
2
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities.利用真实世界证据（RWE）改善慢性淋巴细胞白血病的护理：挑战与机遇。
Curr Hematol Malig Rep. 2020 Aug;15(4):254-260. doi: 10.1007/s11899-020-00584-3.
3
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.
慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项系统评价和荟萃分析
Rev Assoc Med Bras (1992). 2024 Aug 16;70(8):e20240322. doi: 10.1590/1806-9282.20240322. eCollection 2024.
新型靶向治疗时代慢性淋巴细胞白血病的预后检测与治疗模式：来自informCLL注册研究的结果
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):174-183.e3. doi: 10.1016/j.clml.2019.10.009. Epub 2019 Oct 21.
4
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.阿卡拉布替尼联合奥滨尤妥珠单抗治疗初治及复发/难治性慢性淋巴细胞白血病
Cancer Discov. 2020 Mar;10(3):394-405. doi: 10.1158/2159-8290.CD-19-1130. Epub 2020 Jan 8.
5
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
6
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.伊布替尼联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗一线治疗慢性淋巴细胞白血病（ILLUMINATE）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.
7
Relapsed CLL: sequencing, combinations, and novel agents.复发慢性淋巴细胞白血病：测序、联合用药和新型药物。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):248-255. doi: 10.1182/asheducation-2018.1.248.
8
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
9
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
10
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.